Getinge AB stock (SE0000202624): hospital equipment specialist in focus after solid Q1 update

Medical technology group Getinge AB has presented its Q1 2026 figures and confirmed its outlook, keeping the Swedish stock on the radar of health care investors after a volatile 2025. What is behind the latest numbers, and how does the business model generate revenue?

Medical technology company Getinge AB has recently reported its results for the first quarter of 2026, showing continued demand for its hospital and life science equipment and confirming its outlook for the year, according to a company release published in late April 2026 on the investor relations website Getinge IR as of 04/24/2026. The group highlighted stable orders in critical care and surgical workflows, while also pointing to ongoing cost pressures and a cautious capital spending environment among hospitals, as summarized by Reuters as of 04/24/2026.

As of: 05/25/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Getinge B
• Sector/industry: Medical technology / health care equipment
• Headquarters/country: Gothenburg, Sweden
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Intensive care ventilators, operating room equipment, sterilization systems, life science solutions and related services
• Home exchange/listing venue: Nasdaq Stockholm (ticker: GETI B)
• Trading currency: Swedish krona (SEK)

Getinge AB: core business model

Getinge AB is a Sweden-based medical technology group focused on equipment and solutions for hospitals and life science customers. The company’s offerings span intensive care units, operating rooms, sterile reprocessing departments and biopharmaceutical production environments, targeting both public and private health care providers, according to the company profile in its annual report for 2025 published in March 2026 on the investor site Getinge IR as of 03/20/2026. Customers use Getinge products in mission-critical clinical workflows where uptime, regulatory compliance and patient safety are central, which can support recurring service and consumable revenue.

The group organizes its activities in key business areas covering acute care therapies, surgical workflows and life science equipment, each with dedicated product portfolios and service offerings, as described in the same annual report released in March 2026 on the investor relations page Getinge IR as of 03/20/2026. In acute care therapies, Getinge supplies ventilators, anesthesia systems and advanced hemodynamic monitoring solutions for intensive care and operating rooms. In surgical workflows, the company offers operating tables, lights and related infrastructure designed to support efficient procedures and hygiene standards. The life science segment focuses on sterilization, bioreactor and isolation technologies for biopharma and research laboratories, serving a customer base that faces strict regulatory and quality requirements.

The business model combines sales of capital equipment with long-term service contracts, spare parts and consumables, aiming to secure a mix of one-time and recurring income streams, detailed in the 2025 annual report issued in March 2026 on the investor site Getinge IR as of 03/20/2026. Once a hospital installs a Getinge sterilizer or ventilator fleet, it often relies on the manufacturer for regular maintenance, software updates and replacement components, which can create multi-year relationships. For investors, this structure may help smooth revenue over the economic cycle, although large equipment orders can still be lumpy and depend on health care investment budgets in different regions.

Main revenue and product drivers for Getinge AB

In its Q1 2026 report, Getinge indicated that acute care therapies remained a core revenue contributor, supported by demand for ventilators, anesthesia delivery systems and monitoring solutions, according to the quarterly results presentation published in April 2026 on the investor relations website Getinge IR as of 04/24/2026. Although pandemic-driven surges have normalized, the company highlighted replacement cycles for equipment installed earlier in the decade and ongoing investments in intensive care capacity in several markets. The report also pointed to increasing interest in software and connectivity features that integrate Getinge devices into hospital IT networks, potentially opening up new service and upgrade opportunities.

Surgical workflows constitute another important pillar for Getinge, including operating tables, surgical lights and ceiling supply units, together with integrated operating room solutions and planning tools, as outlined in the 2025 annual report published in March 2026 on the investor page Getinge IR as of 03/20/2026. Many hospitals aim to improve operating room utilization and patient throughput, and Getinge positions its products as enablers of more efficient, standardized workflows. The company also offers sterilization and disinfection equipment for central sterile supply departments, which are critical for infection control. This combination can make Getinge a multi-solution supplier for hospitals looking to modernize surgery and reprocessing capabilities in a coordinated way.

Life science solutions form the third major revenue driver, addressing biopharmaceutical production, research laboratories and related facilities. The business includes sterilizers, bioreactors and contamination control systems used in environments with strict regulatory oversight, such as vaccine and biologics manufacturing, according to the company’s segment description in the 2025 annual report released in March 2026 on the investor site Getinge IR as of 03/20/2026. In this area, Getinge competes for capital investment projects that can be substantial in size but are often influenced by the broader funding climate for biopharma and laboratory infrastructure. The group also emphasizes service and validation offerings for these customers, which can add recurring revenue tied to installed systems.

Beyond equipment and core solutions, service contracts and consumables are essential to Getinge’s revenue mix. The company provides preventive maintenance, repair services, training and performance optimization programs for its installed base, and this portfolio is highlighted as a strategic growth area in the Q1 2026 results materials published in April 2026 on the investor relations platform Getinge IR as of 04/24/2026. For investors, the service share of sales can be an indicator of recurring income and resilience during periods when hospitals delay major capital purchases. Consumables linked to certain product families may further support repeat business, although the exact breakdown of revenue by category varies by region and year.

Industry trends and competitive position

Getinge operates in a global medical technology market that is shaped by demographic aging, rising health care expenditure and increasing regulatory requirements for quality and infection prevention. The company notes in its 2025 annual report, published in March 2026 on the investor site, that demand for advanced intensive care, surgical and sterile reprocessing solutions is supported over the long term by structural factors such as chronic disease prevalence and the need to modernize hospital infrastructure Getinge IR as of 03/20/2026. At the same time, health care systems face budget constraints and staff shortages, which can delay procurement decisions and make cost-effectiveness a key competitive criterion.

Competition in Getinge’s segments is significant and includes large multinational medical technology companies as well as specialized niche providers. In intensive care and anesthesia, the group faces rivals with strong global distribution, while in sterilization and life science equipment it competes with firms focused specifically on contamination control and bioprocessing solutions, according to the competitive overview in the 2025 annual report published in March 2026 on the investor platform Getinge IR as of 03/20/2026. To differentiate itself, Getinge emphasizes the breadth of its offering, the integration of hardware, software and services, and its focus on workflows that span multiple hospital departments and life science applications. For investors, the company’s ability to maintain or gain share in key markets, while protecting margins in a competitive and cost-sensitive environment, is an important aspect of the equity story.

Why Getinge AB matters for US investors

Although Getinge is headquartered in Sweden and listed on Nasdaq Stockholm, its products are widely used in North American hospitals and health care systems. The company highlights the Americas, including the United States, as a key region for its acute care therapies and surgical workflows businesses in the 2025 annual report published in March 2026 on the investor site Getinge IR as of 03/20/2026. US hospital capital spending cycles, reimbursement frameworks and regulatory developments therefore have a direct impact on Getinge’s order intake and installed base. For investors watching global medtech names, the stock can be seen as an indirect way to gain exposure to US and international hospital investment trends outside of the major US-listed equipment manufacturers.

In addition, Getinge’s presence in life science equipment connects it to the biopharmaceutical and research ecosystem, where many leading firms are based in the United States. The company notes that its sterilization, bioprocess and contamination control technologies are used in facilities that produce biologics and vaccines, according to the life science segment overview in the 2025 annual report released in March 2026 on the investor platform Getinge IR as of 03/20/2026. For US investors, Getinge therefore offers exposure to both hospital infrastructure and biopharma manufacturing investments across multiple regions, with currency and regulatory dynamics that can differ from those of domestic medtech peers.

Conclusion

Getinge AB’s recent Q1 2026 update underscores the company’s role as a global supplier of equipment and solutions used in intensive care, surgical workflows and life science environments, with a business model that blends capital equipment with services and consumables, according to the quarterly report published in April 2026 on the investor site Getinge IR as of 04/24/2026. Structural drivers such as demographic aging and ongoing hospital modernization support long-term demand, while competition, health care budget pressures and regulatory requirements remain important considerations. For US-focused investors monitoring international medtech opportunities, the Swedish stock offers exposure to hospital and biopharma investment trends across multiple regions without constituting a recommendation to buy or sell.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.